upper
airway
viral
infect
uri
major
caus
absenc
school
work
although
morbid
low
subject
complic
uri
includ
otiti
media
sinus
exacerb
asthma
chronic
obstruct
pulmonari
diseas
copd
enorm
health
impact
despit
major
health
care
consequ
associ
complic
understand
uri
trigger
upper
airway
symptom
caus
exacerb
lower
airway
diseas
remain
limit
articl
review
current
understand
pathogenesi
uri
viral
exacerb
asthma
copd
consid
host
defens
paramet
may
regul
suscept
diseas
exacerb
also
consid
current
potenti
therapeut
approach
treatment
uri
lower
airway
complic
r
complic
uri
manifest
clinic
syndrom
refer
common
cold
frequent
acut
respiratori
ill
experienc
human
adult
experi
cold
year
children
experi
result
accord
center
diseas
control
prevent
million
school
day
lost
annual
unit
state
due
cold
although
common
cold
caus
varieti
differ
viru
type
includ
coronavirus
parainfluenza
viru
respiratori
syncyti
viru
rsv
predomin
viral
pathogen
particularli
autumn
season
human
rhinovirus
hrv
although
simpl
cold
healthi
individu
associ
littl
morbid
long
known
rhinoviru
infect
precipit
exacerb
diseas
includ
otiti
media
sinus
recent
grow
evid
also
implic
uri
predomin
risk
factor
associ
exacerb
asthma
chronic
obstruct
pulmonari
diseas
copd
case
asthma
clear
tempor
relationship
increas
hospit
asthma
exacerb
outbreak
uri
major
spike
earli
septemb
peak
time
hrv
infect
moreov
prospect
studi
use
rtpcr
assist
viral
detect
demonstr
common
respiratori
virus
associ
asthma
exacerb
adult
exacerb
children
although
sever
viral
type
found
exacerb
domin
pathogen
detect
hrv
hrv
also
common
viral
pathogen
associ
asthma
attack
young
children
year
age
present
emerg
room
also
grow
appreci
regard
import
role
uri
trigger
exacerb
copd
recent
studi
indic
half
copd
exacerb
associ
viral
infect
hrv
domin
viral
pathogen
interestingli
respiratori
viral
infect
associ
copd
exacerb
frequent
sever
longer
recoveri
time
abil
uri
serv
precipit
exacerb
asthma
copd
enorm
consequ
term
health
care
cost
patient
qualiti
life
total
health
care
cost
asthma
unit
state
year
estim
billion
acut
exacerb
account
half
total
health
care
cost
diseas
similarli
acut
exacerb
copd
major
caus
hospit
death
account
health
care
cost
diseas
moreov
exacerb
frequenc
major
determin
health
statu
qualiti
life
copd
patient
despit
high
incid
seriou
complic
uri
mechan
virus
induc
upper
airway
symptom
caus
exacerb
lower
airway
diseas
remain
poorli
understood
although
possibl
differ
viral
type
may
induc
outcom
via
variabl
mechan
seem
like
common
aspect
viral
pathogenesi
domin
given
hrv
major
viral
pathogen
associ
cold
exacerb
asthma
copd
focu
current
statu
knowledg
respons
hrv
infect
repres
viral
pathogenesi
indic
differ
viral
type
appropri
clear
uri
associ
increas
airway
inflamm
particular
hrv
infect
lead
increas
number
neutrophil
lymphocyt
upper
airway
hrv
infect
also
induc
neutrophil
recruit
lower
airway
subject
asthma
consist
viral
induc
pattern
mani
acut
asthma
exacerb
seen
clinic
set
character
increas
level
neutrophil
lymphocyt
airway
asthmat
display
neutrophil
profil
show
poor
respons
inhal
corticosteroid
similarli
stabl
copd
associ
characterist
infiltr
bronchial
mucosa
lymphocyt
macrophag
sever
exacerb
copd
associ
increas
neutrophil
lymphocyt
influx
seem
reason
therefor
infer
virus
may
trigger
exacerb
asthma
copd
enhanc
alreadi
exist
inflamm
lower
airway
mechan
viral
infect
abl
enhanc
upper
lower
airway
inflamm
fulli
defin
grow
evid
support
concept
viral
modul
epitheli
function
may
initi
inflammatori
respons
airway
epitheli
cell
primari
target
inhal
pathogen
express
receptor
sever
viral
type
inde
epitheli
cell
cell
type
hrv
detect
thu
far
situ
hybrid
vivo
infect
moreov
strong
evid
upon
experiment
nasal
inocul
hrv
viru
spread
infect
epitheli
cell
lower
airway
suggest
epitheli
infect
may
also
directli
initi
lower
airway
inflammatori
respons
contrast
virus
influenza
rsv
hrv
infect
caus
overt
epitheli
toxic
thu
cytotox
effect
influenza
rsv
may
contribut
sever
symptom
seem
reason
assum
alter
epitheli
biolog
repres
common
pathway
symptom
develop
multipl
viru
type
support
concept
infect
epitheli
cell
hrv
shown
gener
wide
varieti
proinflammatori
chemokin
cytokin
includ
rant
given
sever
product
also
detect
airway
secret
hrv
infect
vivo
like
contribut
recruit
activ
inflammatori
cell
infect
abil
induc
proinflammatori
cytokin
product
epitheli
cell
also
share
virus
exampl
influenza
infect
induc
epitheli
product
rant
rsv
infect
induc
express
wide
rang
chemokin
gene
although
clear
potenti
chemokin
cytokin
induc
inflamm
profil
product
describ
clearli
capac
recruit
plethora
inflammatori
cell
type
airway
despit
rel
select
cellular
profil
seen
infect
vivo
unclear
paramet
regul
limit
pattern
inflammatori
cell
recruit
also
must
acknowledg
understand
mechan
viral
induc
chemokin
product
occur
remain
limit
case
hrv
infect
chemokin
induc
quickli
viral
exposur
seem
requir
viral
replic
gene
induc
sever
hour
postinfect
absolut
depend
upon
replic
viru
although
articl
press
phosphatidylinositol
mitogen
activ
protein
kinas
pathway
implic
viral
induct
chemokin
earli
signal
event
induc
viru
remain
poorli
elucid
similarli
viral
replic
intermedi
doublestrand
rna
rhinoviru
proteas
implic
mediat
late
replic
depend
event
pathway
product
induc
respons
well
defin
moreov
clear
viral
induct
cytokin
chemokin
occur
via
transcript
pathway
involv
nfkb
interferon
regulatori
factor
understand
control
transcript
posttranscript
regul
epitheli
cytokin
chemokin
product
respons
viral
infect
also
limit
requir
studi
delin
aspect
signal
may
uniqu
viral
induct
chemokin
may
provid
ration
basi
target
intervent
studi
select
chemokin
chemokin
receptor
antagonist
requir
provid
definit
answer
key
epitheli
mediat
involv
diseas
pathogenesi
viral
infect
epithelium
initi
proinflammatori
process
subsequ
product
mediat
epitheli
origin
may
contribut
inflammatori
statu
airway
mediat
may
deriv
plasma
cell
type
within
airway
mucosa
mediat
assess
thu
far
rel
virusspecif
other
observ
cold
induc
multipl
viral
type
exampl
rsv
infect
report
associ
gener
virusspecif
ige
increas
releas
histamin
nasal
secret
level
histamin
increas
airway
secret
hrv
infect
moreov
older
antihistamin
display
anticholinerg
sed
properti
reduc
rhinorrhea
cold
second
gener
antihistamin
lack
side
effect
ineffect
contrast
mediat
kinin
leukotrien
associ
infect
due
one
type
common
respiratori
viru
defin
role
mediat
diseas
pathogenesi
requir
studi
effect
select
antagonist
sever
factor
like
play
role
determin
sever
clinic
outcom
upper
airway
viral
respons
includ
suscept
patient
asthma
copd
experi
lower
airway
exacerb
factor
includ
preexist
immun
particular
viral
strain
case
lower
airway
degre
diseas
control
time
infect
anoth
import
factor
like
variabl
individu
host
immun
antivir
respons
infect
although
innat
specif
immun
contribut
host
respons
infect
appear
though
innat
respons
domin
earli
infect
like
help
regul
symptomat
respons
exampl
hrv
infect
elicit
antigenspecif
humor
cellular
immun
respons
usual
detect
diseas
symptom
resolv
may
expect
base
central
role
viral
infect
epitheli
cell
signific
contributor
innat
respons
infect
note
infect
cell
releas
sever
cytokin
chemokin
recruit
activ
cell
immun
system
airway
addit
epitheli
product
nitric
oxid
appear
play
import
role
host
antivir
respons
infect
cultur
epitheli
cell
sever
common
respiratori
virus
lead
mark
upregul
induc
nitric
oxid
synthas
ino
increas
gener
similar
respons
occur
experiment
hrv
infect
vivo
level
epitheli
ino
induct
correl
level
exhal
interestingli
studi
subject
highest
level
exhal
clear
viru
rapidli
lower
symptom
rational
provid
sever
studi
show
exert
direct
antivir
activ
sever
common
respiratori
virus
part
nitrosly
key
thiol
residu
viral
proteas
moreov
shown
also
inhibit
viral
induc
gener
sever
cytokin
chemokin
epitheli
cell
also
note
infect
epitheli
cell
hrv
induc
product
human
peptid
chemotact
immatur
dendrit
cell
express
well
cell
type
contribut
immun
respons
like
play
import
role
link
innat
specif
immun
hrv
also
reduc
extent
influenza
infect
block
fusion
viru
cell
membran
viral
replic
progress
intact
viru
releas
airway
secret
interact
cell
type
may
contribut
immun
respons
presum
exampl
dendrit
cell
initi
antigen
present
cell
airway
lymph
node
initi
specif
immun
respons
addit
monocyt
macrophag
may
releas
addit
cytokin
includ
interferon
stimul
varieti
interferon
ifn
stimul
gene
isg
collect
limit
viru
replic
spread
tradit
approach
mitig
effect
uri
focus
symptomat
relief
although
approach
gener
modest
success
topic
anticholinerg
ipratropium
bromid
reduc
rhinorrhea
effect
mimick
degre
note
older
first
gener
antihistamin
known
also
anticholinerg
properti
similarli
oral
adrenerg
drug
modest
benefit
term
reduc
nasal
blockag
topic
agent
greater
efficaci
suffer
issu
rebound
somewhat
greater
reduct
total
symptom
observ
experiment
hrv
infect
combin
togeth
first
gener
antihistamin
chlorpheniramin
ibuprofen
administ
begin
h
viral
challeng
although
repres
import
proof
concept
regard
effect
combin
antivir
compound
convent
compound
symptomat
relief
practic
util
combin
limit
cost
factor
also
grow
literatur
use
natur
remedi
treatment
cold
although
rational
use
zinc
treatment
cold
well
establish
multipl
studi
evalu
effect
variou
zinc
salt
regard
overal
result
studi
inconclus
recent
wellcontrol
trial
howev
found
zinc
salt
extrem
modest
effect
reduc
symptom
experiment
hrv
infect
ineffect
natur
cold
similarli
echinacea
ginseng
wide
report
herbal
remedi
cold
trial
evalu
agent
small
gener
conflict
data
recent
random
trial
rel
larg
number
subject
report
modest
efficaci
ginseng
extract
reduc
frequenc
natur
cold
found
signific
effect
extract
echinacea
experiment
hrv
infect
major
issu
regard
trial
herbal
remedi
cours
standard
extract
use
across
studi
inde
given
ident
propos
activ
ingredi
unknown
imposs
know
standard
trial
limit
analyz
effect
nasal
symptom
never
evalu
effect
viral
exacerb
asthma
copd
given
data
report
howev
seem
unlik
provid
major
benefit
inde
interest
question
whether
drug
current
use
treatment
asthma
copd
benefici
effect
viral
exacerb
doubt
use
corticosteroid
long
act
bagonist
leukotrien
receptor
antagonist
alon
combin
maintain
optim
asthma
control
proven
efficaci
reduc
number
asthma
exacerb
use
oral
corticosteroid
earli
exacerb
help
prevent
relaps
effect
basal
inflamm
howev
may
necessarili
translat
effect
viralspecif
inflamm
defin
studi
effect
medic
asthma
copd
exacerb
known
viral
origin
corticosteroid
littl
efficaci
hrvinduc
cold
interest
asthmat
display
promin
sputum
neutrophilia
perhap
indic
viral
etiolog
poorli
respons
inhal
corticosteroid
limit
altern
therapeut
approach
viral
induc
airway
diseas
continu
sought
obviou
strategi
use
antivir
approach
influenza
vaccin
clearli
effect
reduc
upper
airway
symptom
prevent
lower
diseas
exacerb
induc
viru
winter
month
unfortun
vaccin
approach
feasibl
hrv
given
larg
number
viral
serotyp
thu
far
proven
unsuccess
case
rsv
infect
neutral
antibodi
prophylaxi
proven
effect
prevent
rsvinduc
bronchiol
cost
factor
limit
broader
util
major
feasibl
issu
would
aris
use
approach
hrv
select
antivir
approach
shown
promis
case
influenza
neuraminidas
inhibitor
avail
sever
year
proven
clinic
efficaci
reduc
develop
sever
symptom
least
two
approach
also
use
develop
potenti
antivir
agent
hrv
novel
capsidbind
inhibitor
pleconaril
prevent
viral
uncoat
natur
cold
oral
pleconaril
mg
administ
three
time
daili
led
signific
modest
reduct
symptom
also
shorten
report
durat
cold
concern
regard
effect
cytochrom
howev
preclud
develop
oral
treatment
altern
antivir
approach
use
hrv
infect
target
inhibit
viral
proteas
necessari
cleavag
viral
polyprotein
thu
replic
topic
administr
one
inhibitor
ruprintrivir
significantli
inhibit
symptom
experiment
hrv
infect
even
administ
begin
h
infect
although
multipl
daili
dose
requir
neither
drug
evalu
abil
limit
hrvinduc
exacerb
lower
airway
diseas
upper
respiratori
tract
viral
infect
complic
lead
signific
burden
health
care
system
throughout
world
current
treatment
less
ideal
greater
insight
molecular
basi
common
virus
induc
upper
lower
airway
symptom
need
altern
therapeut
approach
develop
ration
delin
specif
cytokin
chemokin
key
contributor
diseas
pathogenesi
elucid
signal
pathway
select
viral
modul
epitheli
cell
function
may
identifi
novel
target
therapi
altern
endogen
enhanc
key
host
antivir
host
defens
molecul
topic
administr
molecul
may
provid
altern
approach
reduc
sequela
viral
infect
